HRSA's Office of Pharmacy Affairs has
developed audit guidelines and a dispute resolution process for the
Drug Pricing Program which necessitate certain reporting and record
keeping requirements when there is reasonable cause to believe a
violation of section 340B(a)(5)(A) or (B) has occurred. These
requirements provide a formal dispute resolution process for audits
and other disputes for covered entities and participating drug
manufacturers.
PL:
Pub.L. 102 - 585 602 Name of Law: Limitations on Prices of
Drugs Purchased by Certain Clinics and Hospitals
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.